Factors affecting the uptake of new medicines in secondary care - A literature review

Journal of Clinical Pharmacy and Therapeutics

Volumn 33, Issue 4, 2008, Pages 339-348

  Chauhan, D ^b   Mason, A ^a  

^a UNIVERSITY OF YORK   (United Kingdom)

^b Office of Health Economics   (United Kingdom)

Author keywords

Diffusion of innovation; Pharmaceutical preparations; Professional practice; Review; Secondary health care; Specialist physicians

Indexed keywords

NEW DRUG;

COST EFFECTIVENESS ANALYSIS; DRUG APPROVAL; DRUG CHOICE; DRUG COST; DRUG MARKETING; DRUG MECHANISM; ECONOMIC ASPECT; MEDICAL CARE; MEDICAL DECISION MAKING; MEDICAL SPECIALIST; PRESCRIPTION; REVIEW; UNITED KINGDOM; CLINICAL PRACTICE; DECISION MAKING; DRUG UTILIZATION; ECONOMICS; FACTUAL DATABASE; HUMAN; PATIENT PARTICIPATION; PHYSICIAN; PRACTICE GUIDELINE; PSYCHOLOGICAL ASPECT; STATISTICS;

DATABASES, FACTUAL; DECISION MAKING; DRUG UTILIZATION; GREAT BRITAIN; HUMANS; PATIENT PARTICIPATION; PHYSICIAN'S PRACTICE PATTERNS; PHYSICIANS; PRACTICE GUIDELINES AS TOPIC;

EID: 49849103208     PISSN: 02694727     EISSN: 13652710     Source Type: Journal    
DOI: 10.1111/j.1365-2710.2008.00925.x     Document Type: Review

References (44)

1. Pharmaceutical Industry Competitiveness Task Force (PICTF). (2002) Competitiveness and performance indicators 2002. London: Department of Health and Association of the British Pharmaceutical Industry, 1-68.
2. Pharmaceutical Industry Competitiveness Task Force (PICTF). (2005) Competitiveness and performance indicators 2005. London: Department of Health, 1-70.
3. Mason A. (2006) Factors affecting the uptake of new medicines. York, UK: The University of York.
4. Sussex J, Mason A, Pritchard C, Yuen P (2003) Headroom for innovation in primary care: turning higher NHS spending into more and better health care. London: OHE Consulting.
5. Mason A (2008) New medicines in primary care: a review of influences on general practitioner prescribing. Journal of Clinical Pharmacy and Therapeutics, 33, 1-10.
6. Spitz B (2007) Medicaid agencies as managed care organisations: an "actuarially sound" solution? Journal of Health Politics, Policy & Law, 32, 379-413.
7. Bonair A, Persson J (1996) Innovation and diffusion of health care technologies. In: Szczepura A, Kankaanpaa J, eds. Assessment of health care technologies. Chichester: Wiley, 17-28.
8. Prosser H, Walley T (2006) New drug prescribing by hospital doctors: the nature and meaning of knowledge. Social Science & Medicine, 62, 1565-1578.
9. Christensen AH, Logan RP, Noach LA, Gjorup T (1994) Do clinicians accept the role of Helicobacter pylori in duodenal ulcer disease: a survey of European gastroenterologists and general practitioners. Journal of Internal Medicine, 236, 501-505.
10. Peay MY, Peay ER (1994) Innovation in high risk drug therapy. Social Science & Medicine, 39, 39-52.
11. McGettigan P, Golden J, Fryer J, Chan R, Feely J (2001) Prescribers prefer people: the sources of information used by doctors for prescribing suggest that the medium is more important than the message. British Journal of Clinical Pharmacology, 51, 184-189.
12. Pearson SA, Rolfe I, Smith T (2002) Factors influencing prescribing: an intern's perspective. Medical Education, 36, 781-787.
13. Corrigan MH, Glass HE (2005) Physician participation in clinical studies and subsequent prescribing of new drugs. Pharmacy and Therapeutics, 30, 60-66.
14. Walley T, Folino-Gallo P, Schwabe U, van Ganse E (2004) Variations and increase in use of statins across Europe: data from administrative databases. BMJ, 328, 385-386.
15. Pincus HA, Tanielian TL, Marcus SC, Olfson M, Zarin DA, Thompson J, Zito JM (1998) Prescribing trends in psychotropic medications: primary care, psychiatry, and other medical specialties. Journal of the American Medical Association, 279, 526-531.
16. Helin-Salmivaara A, Huupponen R, Virtanen A, Klaukka T (2005) Adoption of celecoxib and rofecoxib: a nationwide database study. Journal of Clinical Pharmacy & Therapeutics, 30, 145-152.
17. Harrold LR, Field TS, Gurwitz JH (1999) Knowledge, patterns of care, and outcomes of care for generalists and specialists. [see comment]. Journal of General Internal Medicine, 14, 499-511.
18. Anonymous. The NHS in action: Dr Lionel Joyce, Chief Executive, Newcastle City: NHS Trust. Government Business, 9, 25-27, 5 January 1998.
19. Jones MI, Greenfield SM, Bradley CP, Jowett S (2000) Prescribing new drugs: a survey of hospital consultants in the West Midlands. International Journal of Pharmacy Practice, 8, 285-290.
20. Fretheim A, Oxman AD (2005) International variation in prescribing antihypertensive drugs: its extent and possible explanations. BMC Health Services Research, 5, 21.
21. Jones MI, Greenfield SM, Bradley CP (2001) Prescribing new drugs: qualitative study of influences on consultants and general practitioners. BMJ, 323, 378-381.
22. Griffin JP, Griffin TD (1993) The economic implications of therapeutic conservatism. [see comment]. Journal of the Royal College of Physicians of London, 27, 121-126.
23. Lexchin J (2002) Should doctors be prescribing new drugs? International Journal of Risk & Safety in Medicine, 15, 213-222.
24. Foot B, Foy R, Chakravarthy U, Wormald R (2004) Increasing use of a new health technology during the wait for NICE guidance: findings from the third national tracker survey of photodynamic therapy. Journal of Public Health, 26, 52-55.
25. Poulsen RL (1992) Some current factors influencing the prescribing and use of psychiatric drugs. Public Health Reports, 107, 47-53.
26. Higgins MP, Tully MP (2005) Hospital doctors and their schemas about appropriate prescribing. Medical Education, 39, 184-193.
27. Griffin JP (1995) Therapeutic conservatism or therapeutic fossilisation? International Pharmacy Journal, 9, 19-26.
28. Wieringa NF, Denig P, De Graeff PA, Vos R (2001) Assessment of new cardiovascular drugs: relationships between considerations, professional characteristics, and prescribing. International Journal of Technology Assessment in Health Care, 17, 559-570.
29. Seymour MT, Stenning SP, Cassidy J (1997) Attitudes and practice in the management of metastatic colo-rectal cancer in Britain. Colorectal Cancer Working Party of the UK Medical Research Council. Clinical Oncology (Royal College of Radiologists), 9, 248-251.
30. Ferlie E, Fitzgerald L, Wood M (2000) Getting evidence into clinical practice: an organisational behaviour perspective. Journal of Health Services & Research Policy, 5, 96-102.
31. Centre for Reviews and Dissemination (2001) Undertaking systematic reviews of research on effectiveness: CRD's guidance for those carrying out or commissioning reviews, 2nd edn. CRD Report 4. York, UK: The University of York.
32. Booth-Clibborn N, Packer C, Stevens A (2000) Health technology diffusion rates. Statins, coronary stents, and MRI in England. International Journal of Technology Assessment in Health Care, 16, 781-786.
33. Galloway M (2004) Is the DoH failing people with schizophrenia? Hospital Doctor, January 15, 24-25.
34. Steffensen FH, Olesen F, Sorensen HT (1995) Implementation of guidelines on stroke prevention. Family Practice, 12, 269-273.
35. Kasje WN, Denig P, De Graeff PA, Haaijer-Ruskamp FM (2004) Physicians' views on joint treatment guidelines for primary and secondary care. International Journal for Quality in Health Care, 16, 229-236.
36. Glass HE (2004) Do clinical grant payment practices in phase 3 clinical trials influence subsequent clinical investigator prescribing behavior? Disease Management, 7, 77-87.
37. Ruof J, Mittendorf T, Pirk O, von der Schulenburg JM (2002) Diffusion of innovations: treatment of Alzheimer's disease in Germany. Health Policy, 60, 59-66.
38. Partnership Working Group (2007) Qualitative analysis of variation in uptake of medicines across the NHS in England. London: Department of Health and the Association of British Pharmaceutical Industry, 1-49.
39. Department of Health (2006) Best research for best health. A new national health research strategy. London: Crown Copyright DH Publications Orderline, 1-44.
40. The Academy of Medical Sciences (2003) Strengthening clinical research. London: Academy of Medical Sciences, 1-50.
41. Nilsson Bagenholm E, Hoeg S (2004) Agreement between the Swedish Medical Association and the Swedish Association of the Pharmaceutical Industry concerning forms of cooperation between pharmaceutical companies and doctors. Stockholm: The Swedish Medical Association and the Swedish Association of the Pharmaceutical Industry. Available at: http://www.lif.se/ cs/default.asp?id= 6899.
42. Tayside New Medicines Implementation Panel (2005) Recommended procedures governing the activities of medical representatives within NHS Tayside hospitals. Tayside Prescriber-Tayside D & TC Supplement, 48:6. Available at: http://www.nhstay sideadtc.scot.nhs.uk/approved/bulletin/adtcsupp/ 2005/no%2048.pdf.
43. Tobin S (2005) Time for a modern pharmaceutical sales force. London: Grosvenor Gardens, Frost & Sullivan Market Insight, 1-3. Available at: http://www.frost.com/prod/servlet/market-insight-print.pag?docid=37263757.
44. Dyer C (2006) Patient takes her fight for trastuzumab to the High Court. BMJ, 332, 320.